Dr. Reddy’s Laboratories (RDY) – Investment Analysts’ Recent Ratings Updates

A number of firms have modified their ratings and price targets on shares of Dr. Reddy’s Laboratories (NYSE: RDY) recently:

• 10/26/2026 – Dr. Reddy’s Laboratories was upgraded by JPMorgan Chase & Co. from “underweight” to “neutral”.
• 10/25/2026 – Dr. Reddy’s Laboratories was upgraded by Jefferies Financial Group from “underperform” to “hold”. They now have a $13.90 price target on the stock.
• 10/21/2026 – Dr. Reddy’s Laboratories had its “hold (c-)” rating reaffirmed by Weiss Ratings.
• 10/17/2026 – Dr. Reddy’s Laboratories was upgraded by Wall Street Zen from “sell” to “hold”.
• 10/12/2026 – Dr. Reddy’s Laboratories was upgraded by BNP Paribas Exane to “outperform”. They now have a $14.80 price target on the stock.
• 9/29/2026 – Dr. Reddy’s Laboratories was upgraded by Citigroup from “sell” to “buy”. They now have a $1,450.00 price target on the stock, up from $1,040.00.

Dr. Reddy’s Laboratories Stock Performance

Dr. Reddy’s Laboratories stock traded up $0.38 during mid-day trading on Wednesday, reaching $14.68. 1,111,702 shares of the company’s stock were exchanged, compared to its average volume of 2,545,409. The business’s fifty day simple moving average is $12.62 and its 200 day simple moving average is $13.23. The company has a quick ratio of 1.40, a current ratio of 1.93 and a debt-to-equity ratio of 0.03. Dr. Reddy’s Laboratories Ltd has a one year low of $11.36 and a one year high of $15.67. The firm has a market capitalization of $12.25 billion, a PE ratio of 39.66, a P/E/G ratio of 2.94 and a beta of 0.31.

Dr. Reddy’s Laboratories (NYSE:RDY) last posted its quarterly earnings data on Saturday, October 24th. The company reported $0.12 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.10 by $0.02. The business had revenue of $903.89 million during the quarter, compared to the consensus estimate of $894.94 million. Dr. Reddy’s Laboratories had a net margin of 8.56% and a return on equity of 7.91%. On average, sell-side analysts expect that Dr. Reddy’s Laboratories Ltd will post 0.45 earnings per share for the current year.

Dr. Reddy’s Laboratories Limited is a global pharmaceutical company headquartered in Hyderabad, India. Founded in 1984 by Dr. Kallam Anji Reddy, the company develops, manufactures and markets medicines intended to make healthcare more accessible.

Its business includes generic prescription drugs, active pharmaceutical ingredients, biosimilars, specialty products and over-the-counter consumer healthcare products. Dr. Reddy’s offers medicines across therapeutic areas such as cardiovascular care, diabetes, oncology, gastrointestinal health, pain management and dermatology.

The company serves patients and healthcare providers in India, the United States, Europe and a range of other international markets, including emerging markets.